Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Total Non-Current Liabilities: 2021-2022

Historic Total Non-Current Liabilities for Foghorn Therapeutics (FHTX) over the last 2 years, with Dec 2022 value amounting to $404.7 million.

  • Foghorn Therapeutics' Total Non-Current Liabilities was N/A to $294.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $294.0 million, marking a year-over-year change of. This contributed to the annual value of $404.7 million for FY2022, which is 4.26% down from last year.
  • Foghorn Therapeutics' Total Non-Current Liabilities amounted to $404.7 million in FY2022, which was down 4.26% from $422.8 million recorded in FY2021.
  • Foghorn Therapeutics' 5-year Total Non-Current Liabilities high stood at $422.8 million for FY2021, and its period low was $404.7 million during FY2022.
  • Over the past 2 years, Foghorn Therapeutics' median Total Non-Current Liabilities value was $413.8 million (recorded in 2021), while the average stood at $413.8 million.
  • Data for Foghorn Therapeutics' Total Non-Current Liabilities shows a maximum YoY fell of 4.26% (in 2022) over the last 5 years.
  • Yearly analysis of 2 years shows Foghorn Therapeutics' Total Non-Current Liabilities stood at $422.8 million in 2021, then dropped by 4.26% to $404.7 million in 2022.